Plenary Session 1: Is There a Future for Intra-Articular Injections in Joint Preservation?
Date/Time: Thursday, April 29, 2021 - 8:30 AM to 10:30 AM
Log in to Add to My Schedule
Clinically recognizable osteoarthritis (osteoarthritis) is late-stage disease that is difficult to reverse. However, symptom and structural progression follow dramatically different timelines for individual patients. At earlier disease states, some of the biological and molecular changes may be reversible. Intra-articular injection of a wide range of pharmacologic, biological, and cellular treatments show promise in delaying OA onset when administered in small animal models early after chemical or surgically induced joint injury. However, this laboratory situation of treating “pre-osteoarthritis” (pre-OA) has few parallels in clinical practice. Because symptoms are poorly correlated with structural changes until late-stage OA in humans, patients are typically unaware of early disease. Consequently, current injection therapies largely provide symptomatic relief of established OA by reducing joint inflammation. Advances in imaging, proteomic, molecular, and mechanical diagnostics may allow for successful treatment of early OA and “pre-OA” where personalized injection therapies based on new developments in cell therapies, molecular biology, and epigenetics may be effective.
Followed by abstract presentations.